![Ingmar Bruns](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 161 902 $ al 31/08/2026
Ingmar Bruns is currently the Chief Medical Officer at Zentalis Pharmaceuticals, Inc. He previously held the position of Chief Medical Officer at Trillium Therapeutics, Inc. from 2020 to 2021.
He also worked as the Senior Vice President-Clinical Development at Pieris Pharmaceuticals, Inc. Dr. Bruns obtained a doctorate degree from Universität zu Lübeck.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 30/09/2026 | 43.059 ( 0,05 % ) | 161 902 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 13/11/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| TRILLIUM THERAPEUTICS | Director Técnico/Científico/I+D | 17/11/2021 |
| PIERIS PHARMACEUTICALS | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Trillium Therapeutics, Inc.
 Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
Universität zu Lübeck
 Universität zu Lübeck Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pieris Pharmaceuticals, Inc.
 Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Zentalis Pharmaceuticals, Inc.
 Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
